Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;4(4):241-9.
doi: 10.2174/1874473711104040241.

Cannabinoid hyperemesis syndrome

Affiliations
Review

Cannabinoid hyperemesis syndrome

Jonathan A Galli et al. Curr Drug Abuse Rev. 2011 Dec.

Abstract

Coinciding with the increasing rates of cannabis abuse has been the recognition of a new clinical condition known as Cannabinoid Hyperemesis Syndrome. Cannabinoid Hyperemesis Syndrome is characterized by chronic cannabis use, cyclic episodes of nausea and vomiting, and frequent hot bathing. Cannabinoid Hyperemesis Syndrome occurs by an unknown mechanism. Despite the well-established anti-emetic properties of marijuana, there is increasing evidence of its paradoxical effects on the gastrointestinal tract and CNS. Tetrahydrocannabinol, cannabidiol, and cannabigerol are three cannabinoids found in the cannabis plant with opposing effects on the emesis response. The clinical course of Cannabinoid Hyperemesis Syndrome may be divided into three phases: prodromal, hyperemetic, and recovery phase. The hyperemetic phase usually ceases within 48 hours, and treatment involves supportive therapy with fluid resuscitation and anti-emetic medications. Patients often demonstrate the learned behavior of frequent hot bathing, which produces temporary cessation of nausea, vomiting, and abdominal pain. The broad differential diagnosis of nausea and vomiting often leads to delay in the diagnosis of Cannabinoid Hyperemesis Syndrome. Cyclic Vomiting Syndrome shares several similarities with CHS and the two conditions are often confused. Knowledge of the epidemiology, pathophysiology, and natural course of Cannabinoid Hyperemesis Syndrome is limited and requires further investigation.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Two well-characterized naturally occurring endocannabinoids are anandamide and 2-arachidonoylglycerol. Cannabinoids discovered in the cannabis plant with known effects on the regulation of emesis include tetrahydrocannabinol, cannabidiol, and cannabigerol.
Figure 2
Figure 2
The cannabinoids demonstrate opposing effects on the emesis response. A disruption in this balance causing the pro-emetic properties to overcome the anti-emetic effects may explain the paradox observed in cannabinoid hyperemesis syndrome. Abbreviations: CBD: cannabidiol, CBG: cannabigerol, THC: tetrahydrocannabinol.

References

    1. United States Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Office of Applied Studies. National Survey on Drug Use and Health. ICPSR29621-v1. Ann Arbor, MI: Inter-university Consortium for Political and Social Research [distributor]; 2009. 2010-11-16. - DOI
    1. Foley JD. Adolescent use and misuse of marijuana. Adolesc Med Clin. 2006;17:319–34. - PubMed
    1. European Monitoring Centre of Drugs and Drug Addiction. Annual report 2006: the state of the drugs problem in Europe. Report No: 92-9168-266-7. Office for Official Publications of the European Communities; Luxembourg:
    1. Compton WM, Grant BF, Colliver JD, et al. Prevalence of marijuana use disorder in the United States: 1991–1992 and 2001–2002. JAMA. 2004;291:2214–21. - PubMed
    1. Stinson FS, Ruan WJ, Pickering R, et al. Cannabis use disorders in the USA: prevalence, correlates and co-morbidity. Psychol Med. 2006;36:1447–60. - PubMed

Supplementary concepts